FDA designation fast-tracks a promising therapy for MASH, a silent liver disease tied to metabolic aging and long-term health.

longevity.technology/news/altimmu...

#longevity #FDABreakthrough #Altimmune #Pemvidutide #ObesityTreatment #MetabolicHealth #DrugDevelopment #HealthInnovation

🧬Molecule of the Moment | #Pemvidutide (#ALT801)
A dual GLP-1R / GCGR agonist advancing across metabolic and liver disease indications.
Regulatory milestone: FDA Fast Track designation for #MASH and #AUD. We supports Pemvidutide for research use only. ow.ly/xk8F50XK5pg
#GLP1R

Figure 2. Primary endpoints (A) The least-squares mean proportion of patients with resolution of MASH without worsening of fibrosis after 24 weeks of treatment; error bars represent SE; MASH resolution was defined as at least a 2-point reduction in NAS (scale of 0 to 8, with higher scores indicating more severe disease), no hepatocyte ballooning, and a score of 0 or 1 in the lobular inflammation component of the score, without worsening fibrosis. (B) The least-squares mean proportion of patients with liver fibrosis improvement without worsening of MASH after 24 weeks of treatment, defined as the proportion of patients achieving at least a one-stage improvement in liver fibrosis without worsening of NAS; error bars represent SE. A composite strategy was employed that considered patients with missing outcomes due either to missing biopsies or treatment discontinuations as non-responders. Data were analysed with the use of the chi-square test. MASH=metabolic dysfunction-associated steatohepatitis. NAS=non-alcoholic fatty liver disease activity score.

Another G-force molecule
GLP + glucagon agonist #pemvidutide in MASH

Resolution of MASH, fibrosis impact not seen at this time

www.thelancet.com/journals/lan... in @thelancet.com

How long till someone (?Pfizer) gobbles up Altimmune? @rnflex.bsky.social

Pemvidutide shows promise in treating MASH and aiding weight loss Pemvidutide improves symptoms of metabolic dysfunction-associated steatohepatitis after 24 weeks of treatment, the IMPACT trial suggests.

#MedNews - #Pemvidutide improves symptoms of metabolic dysfunction-associated steatohepatitis after 24 weeks of treatment, the IMPACT trial suggests.

Full story 👉 buff.ly/Ai3eet2

#HepSky #MASH

Investors Encouraged to Join Altimmune, Inc. Fraud Class Action Lawsuit The Schall Law Firm urges affected investors to engage in a class action lawsuit against Altimmune, Inc. for alleged securities fraud violations involving misleading statements regarding drug performance.

Investors Encouraged to Join Altimmune, Inc. Fraud Class Action Lawsuit #United_States #Los_Angeles #Schall_Law_Firm #Altimmune #Pemvidutide

Berger Montague Announces Class Action Lawsuit Against Altimmune for Investors' Rights A class action lawsuit against Altimmune Inc. has been filed, calling attention to a significant drop in stock prices. Investors have until October 6, 2025, to respond.

Berger Montague Announces Class Action Lawsuit Against Altimmune for Investors' Rights #United_States #Berger_Montague #Gaithersburg #Altimmune_Inc. #Pemvidutide